A new trial, not yet recruiting in Seattle:
The idea of mixing doxorubicin and keytruda sounds strange to me since doxorubicin usually causes the lymphocite count to go down and Keytruda is supposed to work by “reactivating” T-lymphocites to make them destroy cancer cells. But who knows? Is Keytruda actually doing something else? Is there enough time for T-lymphocites to react before their count plummets?
Dr. Pollack is mentioning the trial in the following interview:
Seth is my doctor. 
The combination of Pembrolizumab and Doxorubicin will also be tried in North Carolina: